Drug Type CAR-T |
Synonyms- |
Target |
Action modulators, inhibitors |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Phase 2 | China | 09 Nov 2024 | |
| Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | China | 09 Nov 2024 | |
| Pre B-cell acute lymphoblastic leukemia | Phase 2 | China | 09 Nov 2024 | |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | China | 09 Nov 2024 | |
| Recurrent Hematologic Malignancy | Phase 2 | China | 09 Nov 2024 | |
| Relapse multiple myeloma | Phase 2 | China | 09 Nov 2024 | |
| T-Cell Lymphoma | Phase 2 | China | 09 Nov 2024 |





